Effects of Glimepiride Combined with Metformin on Glucose and Lipid Metabolism, Islet Function and Serum miR-126 Expression of Newly Diagnosed Type 2 Diabetes Patients
10.6039/j.issn.1001-0408.2018.04.18
- VernacularTitle:格列美脲联合二甲双胍对初诊2型糖尿病患者糖脂代谢、胰岛功能及血清miR-126表达的影响
- Author:
Xiaoya TAN
1
;
Qiang TONG
Author Information
1. 重庆市南川宏仁医院内二科
- Keywords:
Glimepiride;
Metformin;
Type 2 diabetes;
Blood glucose;
Blood lipid;
Islet function;
miR-126
- From:
China Pharmacy
2018;29(4):505-508
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To investigate the effects of glimepiride combined with metformin on glucose and lipid metabolism, islet function and serum miR-126 expression of newly diagnosed type 2 diabetes patients. METHODS: A total of 100 patients with newly diagnosed type 2 diabetes in Nanchuan Hongren Hospital of Chongqing during Jan. 2014-Jan. 2017 were divided into observation group and control group according to random numble table, with 50 cases in each group. Control group was given Metformin hydrochloride sustained-release tablets (Ⅱ) with initial dose of 0. 5 g, once a day, adjusted to 0. 5 g 12 weeks later, twice a day, maximal dose of 1 g at meal or after meal. Observation group was additionally given Glimepiride tablets 2 mg, once a day, at breakfast, on the basis of control group. Both group were treated at lasted for 24 weeks. The levels of blood glucose (FPG, 2 hPG, HbA1c), blood lipid (TC, TG), islet function (FINS, 2 hINS, FCP, 2 hCP, HOMA-IR), serum miR-126 before and after treatment and the occurrence of ADR were observed in 2 groups. RESULTS: Before treatment, there was no statistical significance in the levels of blood glucose, blood lipid, islet function or serum miR-126 expression between 2 groups (P＞0. 05). After treatment, the levels of blood glucose, blood lipid and HOMA-IR in 2 groups were significantly lower than before treatment, and the levels of blood glucose and HOMA-IR in observation group were significantly lower than control group. The levels of FINS, 2 hINS, FCP and 2 hCP, serum miR-126 expression in 2 groups were significantly higher than before treatment, and the observation group was significantly higher than control group, with statistical significance(P＜0. 05). No obvious ADR was found in 2 groups during treatment. CONCLUSIONS: Glimepiride combined with metformin can significantly improve glucose and lipid metabolism, islet function, and regulate serum miR-126 expression without increasing the occurrence of ADR.
